Head to head
Arcutis Biotherapeutics vs Vertex Pharmaceuticals
Side-by-side on the measures that matter, with a plain-English read. Full detail: ARQT · VRTX
ARQT
Arcutis Biotherapeutics
24.17+1.05%
1-year price shape — +18% over the period
Quant Rating D · 64/100
vs
VRTX
Vertex Pharmaceuticals
505.64+0.66%
1-year price shape — +23% over the period
Quant Rating C · 67/100
1-year performance, rebased to 100
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (67); Vertex Pharmaceuticals has done best over the past year (+23%); Vertex Pharmaceuticals trades cheapest on trailing earnings.
| ARQT | VRTX | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Biotechnology |
| Last price | 24.17 | 505.64 |
| Change today | +1.05% | +0.66% |
| 1-year return | +17.5% | +23.2% |
| Market cap | $3.04B | $128.16B |
| 52-week range | 19.30 – 31.77 | 402.58 – 560.25 |
| Valuation | ||
| P/E (TTM) | 109.86 | 29.45 |
| P/E percentile, own 5-yr range | 97th | 74th |
| P/B | 13.77 | 6.33 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | -0.13 | 15.32 |
| Net profit (TTM) | $-16.34M | $3.88B |
| Revenue (TTM) | $463.98M | $12.59B |
| Revenue growth (YoY) | +59.3% | +12.5% |
| Gross margin | 91.1% | 86.0% |
| Operating margin | 7.4% | 37.9% |
| Net margin | 6.1% | 35.0% |
| Free cash flow (TTM) | $39.15M | $3.80B |
| Ownership & sentiment | ||
| Institutional ownership | 107.6% | 97.2% |
| Insider activity (12mo) | 18 buy / 31 sell | 25 buy / 25 sell |
| Short interest (% of float) | 14.7% | 1.9% |
| Analyst consensus | 100% buy (5) | 88% buy / 8% hold / 4% sell (24) |
| Analyst price target | $37 (+53%) | $580 (+15%) |
| StockVane view | ||
| StockVane Quant Rating | D (64) | C (67) |
| Company | ||
| Employees | 354 | 6,400 |
| Founded | 2016 | 1989 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.